Abbott Laboratories (NYSE:ABT) Shares Sold by Revisor Wealth Management LLC

Revisor Wealth Management LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 34.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,670 shares of the healthcare product maker’s stock after selling 1,388 shares during the quarter. Revisor Wealth Management LLC’s holdings in Abbott Laboratories were worth $306,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Toronto Dominion Bank raised its position in shares of Abbott Laboratories by 2.9% during the 4th quarter. Toronto Dominion Bank now owns 727,351 shares of the healthcare product maker’s stock worth $82,269,000 after purchasing an additional 20,457 shares during the period. Formidable Asset Management LLC raised its stake in shares of Abbott Laboratories by 5.1% during the fourth quarter. Formidable Asset Management LLC now owns 10,774 shares of the healthcare product maker’s stock valued at $1,219,000 after purchasing an additional 524 shares in the last quarter. North Star Asset Management Inc. boosted its holdings in shares of Abbott Laboratories by 1.0% in the fourth quarter. North Star Asset Management Inc. now owns 308,496 shares of the healthcare product maker’s stock valued at $34,894,000 after acquiring an additional 3,176 shares in the last quarter. Retirement Planning Group LLC NY bought a new position in Abbott Laboratories during the 4th quarter valued at $368,000. Finally, GF Fund Management CO. LTD. acquired a new position in Abbott Laboratories during the fourth quarter worth about $4,182,000. Institutional investors own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 949 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the sale, the executive vice president now directly owns 74,381 shares of the company’s stock, valued at approximately $10,277,222.77. The trade was a 1.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Eric Shroff sold 562 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the sale, the senior vice president now owns 31,970 shares of the company’s stock, valued at $4,417,294.90. The trade was a 1.73% decrease in their position. The disclosure for this sale can be found here. Insiders sold 95,278 shares of company stock worth $12,745,859 over the last three months. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ABT shares. Piper Sandler restated an “overweight” rating and issued a $145.00 price target (up previously from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Barclays increased their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an “overweight” rating in a research report on Thursday, April 17th. The Goldman Sachs Group lifted their price objective on Abbott Laboratories from $138.00 to $154.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Wells Fargo & Company lifted their target price on shares of Abbott Laboratories from $136.00 to $147.00 and gave the company an “overweight” rating in a research note on Thursday, April 17th. Finally, Bank of America boosted their price target on Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $142.59.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $131.31 on Friday. The firm’s 50-day moving average is $129.87 and its 200-day moving average is $124.62. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The company has a market cap of $228.46 billion, a price-to-earnings ratio of 17.16, a PEG ratio of 2.52 and a beta of 0.74. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.